In the past 20 years there has been a steady improve; ment in the shor
t term prognosis of patients with myocardial infarction,(1) following
the introduction of beta blockers, thrombolysis, and aspirin. Patients
treated with thrombolytic drugs have a lower overall mortality after
myocardial infarction but remain at risk of non-fatal reinfarction or
death, and in one study almost half of all survivors of acute myocardi
al infarction died or suffered a further ischaemic event within three
years.(2) It is therefore important to have a strategy to identify pat
ients at high risk, to reduce the subsequent development of cardiac fa
ilure and mortality, and to have effective measures for secondary prev
ention to reduce the incidence of reinfarction as well as to promote r
ehabilitation.